financetom
Business
financetom
/
Business
/
Toyota aims to ramp up China production in a strategy pivot, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Toyota aims to ramp up China production in a strategy pivot, sources say
Nov 10, 2024 7:33 PM

By Maki Shiraki

TOKYO (Reuters) - Toyota ( TM ) aims to make at least 2.5 million vehicles a year in China by 2030, three people said, an overhaul that will see it bring its Chinese sales and production operations closer together and allow local executives a freer hand in development.

The plan, which has not been previously reported, represents a strategic pivot by the world's top selling automaker in the world's largest car market, underlining its ambition to claw back business lost to BYD and other local players in recent years.

Toyota's ( TM ) strategy is in contrast to that of other global automakers, including Japanese ones, that are either scaling back or pulling out of China.

It aims to boost production to as much as 3 million vehicles a year by the end of the decade, two of the people said. However, it has stopped short of establishing a formal target, the three people said. All of the people declined to be identified because the matter has not been made public.

The bigger number represents a 63% increase on the record 1.84 million vehicles it produced in China in 2022. Last year it produced 1.75 million vehicles there.

Toyota ( TM ) has informed some suppliers of the intended ramp-up, in the hope of reassuring parts makers of its commitment to China and thereby securing its supply chain, the people said.

In response to questions from Reuters, Toyota ( TM ) said in a statement: "With the intense competition in the Chinese market, we are constantly considering various initiatives". It said it would continue to work on making "ever-better cars" for the Chinese market.

The Japanese automaker aims to bring the sales and production operations of its two Chinese joint ventures closer together, to improve efficiency, two of the people said.

It also intends to transfer as much of the development responsibility as possible to China-based staff who have a better grasp of local market preferences, particularly around electrified and connected car technology, two of the people said.

'TOO LATE'

The moves signal a growing awareness within Toyota ( TM ) that it needs to rely more on local staff to take charge and speed up product development in China, one of the people said, adding that otherwise "it will be too late".

Legacy automakers, Toyota ( TM ) included, have been outmaneuvered in China as domestic EV makers rapidly roll out affordable, battery-powered cars with advanced technology.

Last year Toyota ( TM ) announced plans to deepen cooperation among its R&D centre in Jiangsu province and its two local joint ventures.

One problem, representative of Toyota's ( TM ) broader woes, is that vehicles developed independently by joint venture partners are selling better than those produced with Toyota ( TM ).

For instance, FAW Group's Hongqi brand and GAC Group's Aion EV both outsell respective models from FAW Toyota Motor and GAC Toyota Motor. Toyota ( TM ) now intends to better incorporate the know-how of local partners in its cars.

Currently, the same vehicle is produced at each of the two joint ventures and sold with a different design and company name - so-called "twinned vehicles". Going forward, production for each car will be consolidated at one of the joint ventures, two of the people said.

The models will be made available at dealerships of both JVs.

As Japanese automakers have been hit, so have Japanese parts suppliers with operations in China.

Toyota ( TM ) announced at its earnings on Wednesday that operating income in China fell during the first half of the financial year mainly due to higher marketing costs brought about by heavy price competition against Chinese brands.

Amid that competition, Mitsubishi Motors Corp ( MMTOF ) has withdrawn from China, while Honda Motor ( HMC ) and Nissan Motor ( NSANF ) have decided to reduce local production capacity.

(Reporting by Maki Shiraki; Editing by Nobuhiro Kubo, David Dolan and Muralikumar Anantharaman)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Sep 11, 2024
05:10 PM EDT, 09/10/2024 (MT Newswires) -- Samir Desai, Executive Vice President, Chief Digital & Technology Officer, on September 06, 2024, sold 19,041 shares in Abercrombie & Fitch ( ANF ) for $2,501,264. Following the Form 4 filing with the SEC, Desai has control over a total of 27,985 shares of the company, with 27,985 shares held directly. SEC Filing:...
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sep 11, 2024
05:00 PM EDT, 09/10/2024 (MT Newswires) -- Ric Smith, Chief Product & Technology Officer, on September 06, 2024, sold 51,052 shares in Sentinelone ( S ) for $1,140,682. Following the Form 4 filing with the SEC, Smith has control over a total of 585,647 shares of the company, with 585,647 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1583708/000158370824000078/xslF345X05/wk-form4_1726001520.xml ...
BridgeBio to stop development of therapy for genetic disorder
BridgeBio to stop development of therapy for genetic disorder
Sep 11, 2024
Sept 10 (Reuters) - BridgeBio Pharma ( BBIO ) said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland. The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment. (Reporting by Puyaan Singh; Editing by Shinjini Ganguli)...
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Sep 11, 2024
05:02 PM EDT, 09/10/2024 (MT Newswires) -- Westaim ( WEDXF ) after trade Tuesday said it sold all its remaining 1.91-million shares in Skyward Specialty Insurance Group. The investment-holding company said proceeds, less commissions, were approximately US$79 million. Westaim's ( WEDXF ) remaining investments include significant interests in Arena and the Arena FINCOs. The company's shares closed down $0.04 to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved